A super-trail molecule comprising two trail trimers
US-2024254193-A1 · Aug 1, 2024 · US
Powerful MHC-class II peptides derived from survivin
US9498512B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9498512-B2 |
| Application number | US-201213526597-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 19, 2012 |
| Priority date | May 14, 2008 |
| Publication date | Nov 22, 2016 |
| Grant date | Nov 22, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated nucleic acid sequence encoding: a peptide consisting of SEQ ID NO: 3. 2. An expression vector comprising the isolated nucleic acid sequence of claim 1 . 3. An isolated host cell comprising the expression vector of claim 2 . 4. The isolated host cell of claim 3 , wherein said host cell is an antigen presenting cell. 5. The isolated host cell of claim 3 , wherein said host cell is a dendritic cell.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
specific for leukemia · CPC title
Lectin superfamily, e.g. CD23, CD72 · CPC title
against material from animals or humans · CPC title
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9498512B2 cover?
- The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune res…
- Who is the assignee on this patent?
- Rammensee Hans-Georg, Stevanovic Stefan, Gouttefanges Cecile, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/4747. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).